Volkmar Mueller

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 854 citations

End-of-study Results, Breast Oncology, Medicine +8

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

Nancy U. Lin, Virginia F. Borges, Carey K. Anders et al. · Journal of Clinical Oncology · 2020 · 521 citations · Full text

Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis

Giuseppe Curigliano, Volkmar Mueller, Virginia F. Borges et al. · Annals of Oncology · 2021 · 201 citations · Full text

Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status

Tanja Fehm, Sven Becker, Silke Duerr‐Stoerzer et al. · Breast Cancer Research · 2007 · 194 citations · Full text

Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases

Nancy U. Lin, Rashmi K. Murthy, Vandana G. Abramson et al. · JAMA Oncology · 2022 · 184 citations · Full text